PTC Therapeutics Company Profile (NASDAQ:PTCT)

Analyst Ratings

Consensus Ratings for PTC Therapeutics (NASDAQ:PTCT) (?)
Ratings Breakdown: 8 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: $39.80 (454.32% upside)

Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)
Show:
DateFirmActionRatingPrice TargetActions
7/20/2016WedbushReiterated RatingNeutral$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Jefferies GroupReiterated RatingHold$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016Royal Bank Of CanadaReiterated RatingSector Perform$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016Barclays PLCBoost Price TargetOverweight$40.00 -> $100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Bank of America Corp.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Citigroup Inc.DowngradeBuy -> Neutral$90.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$81.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/16/2015Roth CapitalReiterated RatingHold$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2015Deutsche Bank AGReiterated RatingBuy$115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for PTC Therapeutics (NASDAQ:PTCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
5/5/2016Q116($1.26)($1.22)$13.74 million$18.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($1.25)($1.50)$13.04 million$12.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($1.15)($1.27)$9.88 million$9.78 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215($1.20)($1.14)$7.73 million$6.77 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q115($1.20)($1.15)$2.97 million$7.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414($0.83)($0.84)$7.99 million$12.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.90)($0.93)$1.76 million$1.69 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.75)($0.86)$1.71 million$1.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014($0.46)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q413($0.57)($0.75)$6.15 million$4.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q3($0.29)($0.19)$7.20 million$16.29 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PTC Therapeutics (NASDAQ:PTCT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($1.52)($1.00)($1.28)
Q2 20163($1.48)($0.90)($1.28)
Q3 20163($1.37)($0.90)($1.16)
Q4 20163($1.29)($0.50)($0.98)
Q1 20171($0.72)($0.72)($0.72)
Q2 20171($0.92)($0.92)($0.92)
Q3 20171($0.52)($0.52)($0.52)
Q4 20171($0.78)($0.78)($0.78)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for PTC Therapeutics (NASDAQ:PTCT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for PTC Therapeutics (NASDAQ:PTCT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/3/2016Mark RotheraInsiderBuy2,000$6.23$12,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015David P SouthwellDirectorSell23,604$47.52$1,121,662.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Allan Steven JacobsonDirectorSell5,000$50.13$250,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Stuart Walter PeltzCEOSell100,000$54.49$5,449,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Mark Elliott BouldingVPSell56,849$55.04$3,128,968.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Richard AldrichDirectorSell7,000$55.66$389,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Stuart Walter PeltzCEOSell73,700$54.91$4,046,867.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Shane William Charles KovacsCFOSell82,491$55.41$4,570,826.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Neil Gregory AlmsteadEVPSell9,511$68.65$652,930.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015David P SouthwellDirectorSell2,317$69.04$159,965.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Stuart Walter PeltzCEOSell47,200$69.14$3,263,408.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Mark Elliott BouldingVPSell21,142$68.12$1,440,193.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Allan Steven JacobsonDirectorSell16,616$76.00$1,262,816.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Mark RotheraInsiderSell10,700$76.64$820,048.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Michael L KrandaDirectorSell2,500$72.81$182,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Robert J SpiegelInsiderSell1,030$75.10$77,353.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Neil Gregory AlmsteadEVPSell79$70.71$5,586.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Stuart Walter PeltzCEOSell47,201$70.74$3,338,998.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2015Mark RotheraInsiderSell35,000$68.01$2,380,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2015Mark RotheraInsiderSell1,000$67.70$67,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Mark RotheraInsiderSell23,000$65.40$1,504,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Neil Gregory AlmsteadEVPSell26,096$60.26$1,572,544.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Mark RotheraInsiderSell3,000$60.02$180,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Mark RotheraInsiderSell2,300$58.67$134,941.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Claudia De Oliveira Ri HirawatPresidentSell2,149$57.19$122,901.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Mark RotheraInsiderSell9,700$58.04$562,988.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$55.24$120,036.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$39.78$86,441.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2014Claudia De Oliveira Ri HirawatPresidentSell45,661$36.15$1,650,645.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Claudia De Oliveira Ri HirawatPresidentSell43,489$36.18$1,573,432.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Stuart Walter PeltzCEOSell41,501$42.65$1,770,017.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Mark RotheraInsiderSell16,000$44.63$714,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Allan Steven JacobsonDirectorSell2,000$40.16$80,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Mark RotheraInsiderSell8,000$36.24$289,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Shane William Charles KovacsCFOSell1,650$14.74$24,321.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2014Stuart Walter PeltzCEOSell25,487$29.86$761,041.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Claudia De Oliveira Ri HirawatPresidentSell15,320$29.61$453,625.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014David SouthwellDirectorSell2,317$30.93$71,664.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Mark Elliott BouldingVPSell10,049$30.96$311,117.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Neil Gregory AlmsteadVPSell10,859$31.91$346,510.69View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2014Allan Steven JacobsonDirectorSell7,616$31.18$237,466.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Michael KrandaDirectorSell1,186$31.02$36,789.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2014Robert SpiegelInsiderSell1,186$31.75$37,655.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2014Stuart Walter PeltzCEOSell27,414$29.91$819,952.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Hbm Healthcare Investments (Camajor shareholderSell66,667$19.08$1,272,006.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2013Adam KoppelDirectorBuy1,250,000$15.00$18,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2013Hbm Healthcare Investments (CaMajor ShareholderBuy666,676$15.00$10,000,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2013Mark RotheraInsiderBuy25,000$15.00$375,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for PTC Therapeutics (NASDAQ:PTCT)
DateHeadline
07/21/16 06:18 PMWorth Watching Stocks: PTC Therapeutics (PTCT), Pioneer Natural ... - iStreetWire
07/21/16 06:18 PMTrending Stock Analysis: PTC Therapeutics, Inc. (NASDAQ:PTCT) - News Oracle
07/21/16 07:00 AMPTC Therapeutics to Host Conference Call to Discuss Second Quarter Financial Results - [PR Newswire] - SOUTH PLAINFIELD, N.J., July 21, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter financial results ...
07/19/16 06:06 PMHeightened Volatility Spotted on Shares of: PTC Therapeutics, Inc. (NASDAQ:PTCT) - Engelwood Daily
07/18/16 06:05 PMPtc Therapeutics Incorporated (NASDAQ:PTCT) Short Interest Decreased By 14.73% - Consumer Eagle
07/16/16 09:14 AMShares Experiencing a Downtrend: PTC Therapeutics, Inc. (NASDAQ:PTCT) - TGP
07/15/16 04:58 PMPTC Therapeutics, Inc. (NASDAQ:PTCT) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 04:58 PMOption Market: PTC Therapeutics Inc Risk Hits An Extreme High - CML News
07/14/16 06:13 PMEye on Stock Volatility for: PTC Therapeutics, Inc. (NASDAQ:PTCT) - Engelwood Daily
07/14/16 06:13 PMPTC Therapeutics Inc. (PTCT) Drops 5.95% on July 13 - Equities.com
07/14/16 09:35 AMAnalyst Target and Average Rating Watch: PTC Therapeutics, Inc. (NASDAQ:PTCT) - Press Telegraph
07/11/16 10:37 AMBiotechnology Stocks Under the Scanner -- PTC Therapeutics, Inovio Pharma, VIVUS, and Spectrum Pharma
07/08/16 05:58 PMStocks inside Analysts Limelight: CVS Health Corporation (NYSE:CVS) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Street Updates
07/08/16 05:58 PMPTC Therapeutics Inc. (PTCT) Jumps 5.63% on July 07 - Equities.com
07/07/16 06:01 PMPTC Therapeutics : NHS England Enables Access to Translarna(TM) (ataluren) For Patients with Nonsense Mutation Duchenne Muscular Dystrophy
07/07/16 08:48 AMCompany Stock Focus for PTC Therapeutics, Inc. (NASDAQ:PTCT): Which Way Will Shares Head? - Press Telegraph
07/07/16 08:48 AMPTC Therapeutics (PTCT), NHS England Enter Managed Access Agreement for Translarna as mDMD Treatment - StreetInsider.com
07/07/16 07:31 AMNHS England Enables Access to Translarna™ ▼ (ataluren) For Patients with Nonsense Mutation Duchenne Muscular Dystrophy - [at noodls] - SOUTH PLAINFIELD, N.J., July 7, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company and NHS England have successfully negotiated a Managed Access Agreement (MAA) ...
07/07/16 07:19 AM8:19 am PTC Therapeutics negotiates a managed access agreement for Translama for ambulatory patients aged 5 years and older with nonsense mutation Duchenne muscular dystrophy -
07/05/16 05:41 PMAnalysts Update on Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT) , Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Street Updates
07/02/16 05:35 PMPtc Therapeutics Incorporated (NASDAQ:PTCT) Shorts Decreased by 14.73% After Short Covering - Press Telegraph
06/30/16 06:15 PMPTC Therapeutics, Inc. (NASDAQ:PTCT) Updated Price Targets - FTSE News
06/30/16 08:48 AMPTC Therapeutics Inc. (PTCT) Jumps 7.19% on June 28 - Equities.com
06/29/16 05:52 PMPTC Therapeutics Inc. (PTCT) is Trading Lower on Unusual Volume for June 27 - Equities.com
06/28/16 05:52 PMCheck on Share Volatility: PTC Therapeutics, Inc. (NASDAQ:PTCT) - Engelwood Daily
06/25/16 09:42 AMPTC Therapeutics Inc. (PTCT) Jumps 6.06% on June 23 - Equities.com
06/24/16 06:01 PMPTC Therapeutics, Inc. (NASDAQ:PTCT) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 06:01 PMPtc Therapeutics Incorporated (NASDAQ:PTCT) Sellers Increased By 7.49% Their Shorts - Engelwood Daily
06/22/16 05:56 PMPTC Therapeutics (NASDAQ:PTCT) Analyst Rating Consensus - TheFounders Daily
06/22/16 05:56 PMPTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Momentum Hits Weakness - CML News
06/15/16 10:32 AMSnapshot of Recent Traded Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT) , Tenet Healthcare Corporation (NYSE:THC) - Street Updates
06/14/16 10:45 AMBiotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
06/13/16 03:32 PMPTC THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/13/16 08:56 AMAnalytical Report of the Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT), Aegerion Pharmaceuticals, Inc. (NASDAQ ... - Beacon Chronicle
06/13/16 07:19 AMPTC Therapeutics Appoints Dawn Svoronos to Board of Directors - [at noodls] - SOUTH PLAINFIELD, N.J., June 13, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Dawn Svoronos to the company's Board of Directors. Ms. Svoronos most recently ...
06/12/16 05:53 PMStock is down at $7.33 New Analyses from Phase 3 Study 009 of…
06/12/16 05:53 PMPTC Therapeutics (PTCT) Announces Presentation of New Analysis from Translarna Phase 3 in CF
06/11/16 06:09 PMKeep an eye on Analyst Actions: Agilent Technologies, Inc. (NYSE:A) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Street Updates
06/11/16 08:51 AMPTC Therapeutics (PTCT) Announces Presentation of New Analysis from Translarna Phase 3 in CF - StreetInsider.com
06/10/16 09:59 AMNew Analyses from Phase 3 Study 009 of Translarna™ (ataluren) in Patients with Cystic Fibrosis Presented at 39th European Cystic Fibrosis Conference - [at noodls] - SOUTH PLAINFIELD, N.J., June 10, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that new analyses from the company's previous Phase 3, double-blind, placebo-controlled, 48-week ...
06/10/16 08:58 AMWhy PTC Therapeutics Jumped 10% In May - Motley Fool
06/10/16 06:15 AMBiotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too -
06/09/16 08:57 AMCurrent PTC Therapeutics (NASDAQ:PTCT) PT Means Stock Is Worth Almost $40 - iStreetWire
06/09/16 08:57 AMTwo Buzzers to Observe: Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Street Updates
06/08/16 08:59 AMPTC Therapeutics, Inc. (NASDAQ:PTCT) Insider Activities Are in the Air - iStreetWire
06/08/16 08:59 AMPTC Therapeutics Inc. (PTCT) Jumps 7.58% on June 06 - Equities.com
06/07/16 08:43 AMExelixis, Inc. (NASDAQ:EXEL) Edged Up 11.23%: PTC Therapeutics, Inc. (NASDAQ:PTCT), MeetMe, Inc. (NASDAQ ... - KC Register
06/06/16 04:41 PMETF’s with exposure to PTC Therapeutics, Inc. : June 6, 2016 -
06/06/16 09:41 AMAnalysts Rating Overview: Celldex Therapeutics, Inc. (NASDAQ:CLDX) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Street Updates
06/03/16 06:31 PMStock Review and Earnings Check on PTC Therapeutics, Inc. (NASDAQ:PTCT) - HNN

Social

About PTC Therapeutics

PTC Therapeutics logoPTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PTCT
  • CUSIP:
Key Metrics:
  • Previous Close: $7.18
  • 50 Day Moving Average: $7.16
  • 200 Day Moving Average: $11.55
  • P/E Ratio: N/A
  • P/E Growth: 0.15
  • Market Cap: $243.54M
  • Beta: 0.83
  • Current Year EPS Consensus Estimate: $-4.95 EPS
  • Next Year EPS Consensus Estimate: $-3.31 EPS
Additional Links:
PTC Therapeutics (NASDAQ:PTCT) Chart for Sunday, July, 24, 2016